{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:06:46Z","timestamp":1793300806150,"version":"4.5.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Tedizolid, a novel oxazolidinone developed for the treatment of skin and soft tissue infections, exhibits a longer half-life than linezolid, with reduced myelosuppression and neurotoxicity. However, its penetration into the cerebrospinal fluid (CSF) remains poorly characterized. Our case report evaluated the CSF penetration of tedizolid.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case presentation<\/jats:title>\n                  <jats:p>We present a case of parameningeal aseptic meningitis secondary to otogenic skull base osteomyelitis. Tedizolid concentrations in CSF and serum were measured using liquid chromatography and tandem mass spectrometry. The trough CSF concentration of tedizolid was below the limit of quantification, whereas the corresponding serum concentration was within the expected therapeutic range. A brief review of the literature corroborated the observation that CSF penetration of tedizolid was markedly lower than that of linezolid.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Considering the consistently low CSF concentrations of tedizolid, linezolid remains the preferred agent for the treatment of CNS infections.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlaf100","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T07:35:09Z","timestamp":1748763309000},"source":"Crossref","is-referenced-by-count":3,"title":["Insufficient cerebrospinal fluid penetration of tedizolid: a case report"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6345-9685","authenticated-orcid":false,"given":"Xavier","family":"Brousse","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, University Hospital of La R\u00e9union , Saint-Pierre, Reunion Island 97410 ,","place":["France"]},{"name":"Infectious Diseases Unit, University Hospital of Bordeaux , Bordeaux F-33000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-8288","authenticated-orcid":false,"given":"Minh P","family":"L\u00ea","sequence":"additional","affiliation":[{"name":"Pharmacology Department, AP-HP, Bichat Claude Bernard Hospital , Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, IAME, UMR 1137 , Paris F-75006 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0043-7336","authenticated-orcid":false,"given":"Marin","family":"Lahouati","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, University Hospital of Bordeaux , Bordeaux F-33000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0517-6203","authenticated-orcid":false,"given":"Paul","family":"Petitgas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, University Hospital of La R\u00e9union , Saint-Pierre, Reunion Island 97410 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"2025071704413421500_dlaf100-B1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40262-021-01099-7","article-title":"Pharmacokinetics and pharmacodynamics of tedizolid","volume":"61","author":"Iqbal","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2025071704413421500_dlaf100-B2","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/cid\/civ501","article-title":"Tedizolid: the first once-daily oxazolidinone class antibiotic","volume":"61","author":"Burdette","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025071704413421500_dlaf100-B3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"2025071704413421500_dlaf100-B4","doi-asserted-by":"publisher","first-page":"e710","DOI":"10.1093\/cid\/ciab032","article-title":"A phase 3, randomized, double-blind study comparing tedizolid phosphate and linezolid for treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia","volume":"73","author":"Wunderink","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025071704413421500_dlaf100-B5","doi-asserted-by":"publisher","first-page":"ofab351","DOI":"10.1093\/ofid\/ofab351","article-title":"Safety of tedizolid as suppressive antimicrobial therapy for patients with complex implant-associated bone and joint infection due to multidrug-resistant gram-positive pathogens: results from the TediSAT cohort study","volume":"8","author":"Ferry","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025071704413421500_dlaf100-B6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1128\/AAC.03950-14","article-title":"Lack of neuropathological changes in rats administered tedizolid phosphate for nine months","volume":"59","author":"Schlosser","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025071704413421500_dlaf100-B7","doi-asserted-by":"publisher","first-page":"10.1128\/aac.01537-17","DOI":"10.1128\/aac.01537-17","article-title":"In vitro susceptibility testing of tedizolid against isolates of nocardia","volume":"61","author":"Brown-Elliott","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025071704413421500_dlaf100-B8","doi-asserted-by":"publisher","first-page":"e70100","DOI":"10.1111\/cts.70100","article-title":"Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood\u2013brain barrier disruption","volume":"18","author":"Lahouati","year":"2025","journal-title":"Clin Transl Sci"},{"key":"2025071704413421500_dlaf100-B9","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1093\/cid\/ciw861","article-title":"2017 Infectious Diseases Society of America\u2019s clinical practice guidelines for healthcare-associated ventriculitis and meningitis*","volume":"64","author":"Tunkel","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025071704413421500_dlaf100-B10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/phar.1337","article-title":"Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug","volume":"34","author":"Flanagan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2025071704413421500_dlaf100-B11","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.1128\/AAC.03423-14","article-title":"Tedizolid population pharmacokinetics, exposure response, and target attainment","volume":"58","author":"Flanagan","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025071704413421500_dlaf100-B12","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.clinthera.2016.06.014","article-title":"Pharmacokinetics and safety of tedizolid after single and multiple intravenous\/oral sequential administrations in healthy Chinese subjects","volume":"38","author":"Chen","year":"2016","journal-title":"Clin Ther"},{"key":"2025071704413421500_dlaf100-B13","doi-asserted-by":"publisher","first-page":"104420","DOI":"10.1016\/j.yrtph.2019.104420","article-title":"Comparative pharmacokinetics of tedizolid in rat plasma and cerebrospinal fluid","volume":"107","author":"Gu","year":"2019","journal-title":"Regul Toxicol Pharmacol"},{"key":"2025071704413421500_dlaf100-B14","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/j.mmifmc.2022.03.224","article-title":"Diffusion insuffisante du t\u00e9dizolide dans le liquide c\u00e9r\u00e9bro-spinal: 2 cas de nocardiose c\u00e9r\u00e9brale (abstract)","volume":"1","author":"Bouet","year":"2022","journal-title":"M\u00e9d Mal Infect Form"},{"key":"2025071704413421500_dlaf100-B15","doi-asserted-by":"publisher","first-page":"113764","DOI":"10.1016\/j.jpba.2020.113764","article-title":"High-throughput and wide-range simultaneous determination of linezolid, daptomycin and tedizolid in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry","volume":"194","author":"Tanaka","year":"2021","journal-title":"J Pharm Biomed Anal"},{"key":"2025071704413421500_dlaf100-B16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/idr13030076","article-title":"Inadequate cerebrospinal fluid concentrations of available salvage agents further impedes the optimal treatment of multidrug-resistant Enterococcus faecium meningitis and bacteremia","volume":"13","author":"Wenzler","year":"2021","journal-title":"Infect Dis Rep"},{"key":"2025071704413421500_dlaf100-B17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ijantimicag.2016.11.032","article-title":"Myelosuppression-sparing treatment of central nervous system nocardiosis in a multiple myeloma patient utilizing a tedizolid-based regimen: a case report","volume":"49","author":"Matin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2025071704413421500_dlaf100-B18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/antibiotics13010058","article-title":"New antibiotics for the treatment of nosocomial central nervous system infections","volume":"13","author":"Nau","year":"2024","journal-title":"Antibiotics (Basel)"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/4\/dlaf100\/63694541\/dlaf100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/4\/dlaf100\/63694541\/dlaf100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T08:41:40Z","timestamp":1752741700000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf100\/8191445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf100","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,7,2]]},"article-number":"dlaf100"}}